Comparative Pharmacology
Head-to-head clinical analysis: RISVAN versus ZIPRASIDONE MESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RISVAN versus ZIPRASIDONE MESYLATE.
RISVAN vs ZIPRASIDONE MESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Risperidone is an atypical antipsychotic that acts as a serotonin 5-HT2A and dopamine D2 receptor antagonist. It also binds to alpha1-adrenergic and H1 histaminergic receptors.
Ziprasidone mesylate is an atypical antipsychotic with high affinity for serotonin 5-HT2A and dopamine D2 receptors. It also antagonizes 5-HT1D, 5-HT2C, and alpha1-adrenergic receptors, and inhibits serotonin and norepinephrine reuptake.
70 mg orally once daily, with or without food.
20 mg intramuscularly (IM) as needed, not to exceed 40 mg/day; oral: 20 mg twice daily with food, titrated up to 80 mg twice daily. Maximum: 160 mg/day oral.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 20-30 hours in hepatic impairment (Child-Pugh B/C).
Terminal elimination half-life is approximately 2.2 hours (range 1.4–3.6 h) for the mesylate salt; clinical context: requires twice-daily dosing.
Renal: 30% unchanged; Fecal: 65% (biliary excretion of metabolites); 5% other.
Approximately 20% renal, 80% fecal/biliary. Unchanged drug accounts for <1% of renal excretion.
Category C
Category A/B
Atypical Antipsychotic
Atypical Antipsychotic